CONMED (NYSE:CNMD) posts Q3 2026 sales in line with estimates
CONMED (CNMD) reported Q3 2026 revenue of $335.6M, flat year-on-year but in line with estimates. Adjusted EPS of $1.04 beat estimates by 3.7%. The company reconfirmed its full-year revenue guidance of $1.36B and slightly raised its EPS guidance to $4.58. Operating margin decreased to 11.1% from 3.5% year-on-year. Long-term revenue growth has slowed, with a 6.7% CAGR over five years.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data that could influence short-term price action, with modest upside potential balanced by revenue concerns.
Market read
Earnings beat on EPS and guidance raise may prompt modest buying, but flat revenue could limit rally, affecting healthcare sector sentiment.
What to watch
Operating margin improvement and product line diversification could support longer-term upside despite short-term flat sales.
Background
CONMED reported Q3 2026 results, meeting revenue expectations but showing flat year-over-year sales, while EPS beat estimates and guidance was slightly raised.
Ticker impact
Q3 2026 earnings released, revenue in line with estimates and EPS beat, with slightly raised full-year EPS guidance.
modest upside as market prices in EPS beat and guidance raise, but limited by flat revenue
New earnings data provides fresh information; EPS beat and guidance raise are positive, yet revenue flatness tempers enthusiasm.
Market effects
Medical device sector may see modest pressure as CONMED's flat revenue signals broader demand concerns.
U.S. healthcare equities could experience slight pullback pending broader earnings season.
Limited, primarily affects U.S. small- to mid-cap healthcare investors.
Counterpoint
Flat revenue may indicate underlying demand weakness; investors could short on expectation of margin compression.
Key entities
- CompanyCONMED
Medical technology manufacturer reporting Q3 2026 earnings.
